- Home
- REX vs XERS Comparison
REX vs XERS Comparison
Compare REX & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REX | XERS |
|---|---|---|
| Founded | 1980 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | REX | XERS |
|---|---|---|
| Price | $33.99 | $7.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $25.00 | $10.43 |
| AVG Volume (30 Days) | 152.5K | ★ 2.3M |
| Earning Date | 12-04-2025 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.48 | N/A |
| Revenue | ★ $650,756,000.00 | $266,137,000.00 |
| Revenue This Year | $3.27 | $44.77 |
| Revenue Next Year | $17.11 | $27.72 |
| P/E Ratio | $22.64 | ★ N/A |
| Revenue Growth | N/A | ★ 42.05 |
| 52 Week Low | $16.73 | $3.38 |
| 52 Week High | $36.50 | $10.08 |
Technical Indicators
Market Signals| Indicator | REX | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 57.33 | 43.57 |
| Support Level | $33.15 | $7.36 |
| Resistance Level | $35.22 | $7.65 |
| Average True Range (ATR) | 0.90 | 0.29 |
| MACD | 0.05 | -0.05 |
| Stochastic Oscillator | 72.74 | 10.61 |
Price Performance
Historical ComparisonAbout REX REX American Resources Corporation
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).